# Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

> **NCT00036933** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** MUC-2-Globo H-KLH conjugate vaccine
- **BIOLOGICAL:** QS21

## Key facts

- **NCT ID:** NCT00036933
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2013-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036933, "Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00036933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*